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Abstract
Introduction: Patient registries serve an important role in rare disease research, particularly for the
recruitment and planning of clinical trials. The Canadian Neuromuscular Disease Registry was established with the primary objective of improving the future for neuromuscular (NM) patients through
the enablement and support of research into potential treatments.
Methods: In this report, we discuss design and utilization of the Canadian Neuromuscular Disease
Registry with special reference to the paediatric cohort currently enrolled in the registry.
Results: As of July 25, 2017, there are 658 paediatric participants enrolled in the registry, 249 are dystrophinopathies (229 are Duchenne muscular dystrophy), 57 are myotonic dystrophy participants, 98
spinal muscular atrophy participants and 65 are limb girdle muscular dystrophy. A total of 175 patients
have another NM diagnosis. The registry has facilitated 20 clinical trial inquiries, 5 mail-out survey
studies and 5 other studies in the paediatric population.
Discussion: The strengths of the registry are discussed. The registry has proven to be an invaluable
tool to NM disease research and has increased Canada’s visibility as a competitive location for the conduct of clinical trials for NM therapies.
Keywords: Clinical trials; Neuromuscular; Rare disease; Registry; Surveys
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There are over 150 neuromuscular (NM) disorders, as delineated by the World Federation of Neurology (1). The most
common childhood NM diseases are: Duchenne muscular dystrophy (DMD), with an incidence of between 1 in 3500 and 1 in
5000 newborn males; myotonic dystrophy (DM), with a prevalence of between 0.5 and 18.1 in 100,000 worldwide (2,3); and
spinal muscular atrophy (SMA), which has an incidence of 1 in
11,000 live births (4).
Patient registries serve as important tools for organizing
patient clinical and demographic information, as well as accelerating and supporting translational research. Registries are especially important for rare disease communities in the recruitment
and facilitation of clinical trials (5,6). Patient registries such as
the Canadian Neuromuscular Disease Registry (CNDR) provide a platform whereby the target populations can be quickly
and easily identified across a national complement of clinics
facilitating research activities and investigator collaboration.
The CNDR was established in 2011 as a tool that connects
both adult and paediatric Canadians living with a NM disease
with national and international research opportunities. Apart
from planning and recruitment for clinical trials, which has
been the principal activity, survey, epidemiological and natural history studies have been conducted using participants and
patient information obtained from the CNDR (7).
The CNDR is part of a multinational effort to coordinate and
consolidate NM disease registry data to enable broader high-impact research efforts. In this regard, the Translational Research
in Europe for the Assessment and Treatment of Neuromuscular
Disease (TREAT-NMD) Alliance is a global effort configured
to harmonize translational research in NM disease. One of
TREAT-NMD’s main goals is the development of a set of standardized principles and a consistent framework for NM patient
registries. With this framework in place to foster a collaborative environment, the TREAT-NMD Global registry group has
been able to publish large studies addressing important issues
for the NM community (5,8). The CNDR is a participating
member of the TREAT-NMD Global registry alliance and contributes data on behalf of Canadian patients to this important
international collaboration.
The CNDR collects detailed medical data on four rare
paediatric NM diseases collectively known as ‘indexed’ diseases (DMD, DM, SMA and limb girdle muscular dystrophy
[LGMD]). Data are updated at a minimum interval of once in
every 12 months. The registry also enrols other childhood-onset NM disorders, collecting only contact details, basic demographics (e.g., age, gender) and a diagnosis. These diseases are
termed ‘non-indexed diseases’. Depending on resource and
funding availability to support active recruitment and tracking, a non-indexed disease may become an indexed disease. In
this report, we discuss the design and utilization of the registry
and describe the paediatric population currently enrolled. The
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objective of this paper is to raise awareness among Canadian
paediatricians and paediatric subspecialists about the registry
and highlight the valuable nature of this tool for collaborative
research in rare childhood disorders.

METHODS
Objectives
The CNDR aims to improve the future for Canadians with NM
disorders through the enablement and support of research that
enhances the understanding of epidemiology of NM diseases
in Canada, attracts international trial opportunities and fosters
collaboration among Canadian investigators.

Registry design
The CNDR operates as a network of university-affiliated NM
clinics and local principal investigators. Adult and paediatric
clinics function as separate sites even if they are in the same city
or even institution. Although the focus of this paper is on the
paediatric component of the registry, the organization and processes between the adult and paediatric components are identical. Patient enrollment from clinics is supported and overseen
centrally by the CNDR National Office at the University of
Calgary. Each clinic obtains local research ethics board approval
using a standardized ethics package that is common across all
centres.

Patient eligibility and consent
All children and adults living in Canada with a NM condition
are eligible for enrollment into the registry. The majority of
participants enrolled in the registry are enrolled during routine
clinic visits by a research coordinator or clinician. In addition,
patients not attending an affiliated clinic or otherwise without specialist care may self-register by contacting the CNDR
National Office. Any physician in Canada may also refer their
patients to the CNDR by directing them to the CNDR National
Office.

Data collection and management
Clinical data are collected retrospectively by trained research
personnel accessing clinic charting or by the attending physician or a trained research coordinator during a clinic visit.
Identified and de-identified data are directly entered into a
secure web portal. De-identified medical data quality and compliance audited by CNDR National Office staff.

Access to CNDR data
Access to de-identified aggregated registry data is facilitated
through a formal application process. There are two types of
data requests: research proposal requests and statistical data
requests. Research proposals involve the export of de-identified
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CNDR data for research use or use of identified data by CNDR
National Office staff to contact CNDR subjects for research
study participation on behalf of the study team and/or sponsor. Proposals may be submitted by an investigator or sponsor
and must include approval from a relevant ethics board. These
studies are then reviewed by the CNDR Advisory Committee.
Statistical data requests involve an application for aggregated
statistics such as information on the distribution of patients in
Canada by location or by disease group. These requests do not
involve the export of records from the CNDR and are of a data
granularity that does not risk individual identification. These
requests are typically used to inform study feasibility or to provide information for government analysis, charitable inquiries
or pharmaceutical company clinical trial planning. Typically,
the request is driven by the need to examine aggregate data to
better understand patient numbers and characteristics across
Canada. All data inquiries are reviewed by the CNDR Advisory
Committee. In addition to exporting data and providing statistical information, the CNDR also facilitates notification through
mail-outs to eligible study participants and can provide custom
study data collection or facilitate the collection of anonymized
study data through survey mail-outs.

Ten of the 24 CNDR clinics recruit paediatric participants
(Table 1). Figure 1 shows the breakdown of all paediatric NM
diseases. Dystrophinopathies account for the largest proportion
of participants, followed by SMA, LGMD and DM, together
making up 71.3% of the entire paediatric population. Table 2
summarizes the genetic characteristics of these index disease
participants, and Table 3 summarizes other clinical information
such as ventilation status.
Since its launch, the CNDR has approved 30 studies that
involve the paediatric population: 20 were clinical trial inquiries, 5 were mail-out surveys and 5 were other studies. The
five mail-out survey studies included two that examined the
quality of life in boys with DMD (9), parent-reported disease burden of congenital and childhood-onset DM (10); an
access to technology survey for individuals with DM, and a
respiratory needs survey in boys with DMD and SMA. Five
other studies included a study of congenital DM; a study of
a respiratory intervention in children; an inquiry regarding
ventilation support use in paediatric patients with type I DM;
an inquiry regarding steroid use, growth and walking ability
in DMD patients; and a study on genetics of dystrophinopathies and disease severity.

RESULTS

DISCUSSION

The CNDR began paediatric enrollment in June of 2011
and as of July 25, 2017 totals 658 participants (19% of
registry overall).

The CNDR has grown to be a valuable national tool in the facilitation of research in children with NM disorders. From an international perspective, the CNDR is one of 49 registries that enroll DMD

Table 1. Current and former paediatric neuromuscular clinics participating in the Canadian Neuromuscular Disease Registry

City
Current
Vancouver, BC
Calgary, AB
Toronto, ON
London, ON
Ottawa, ON
Kingston, ON
Montreal, QC
Fredericton, NB

Halifax, NS
Winnipeg, MB
Past
Mississauga, ON

Clinical site

Academic institution

Site principal investigators

BC Children’s Hospital
Alberta Children’s Hospital
Holland Bloorview Kids Rehabilitation
Hospital
Thames Valley Children’s Centre
Children’s Hospital of Eastern Ontario

University of British Columbia
University of Calgary
University of Toronto

Dr. Kathryn Selby
Dr. Jean Mah
Dr. Laura McAdam and
Dr. Doug Biggar
Dr. Craig Campbell
Dr. Anna McCormick and
Dr. Hugh McMillan
Dr. Garth Smith

Western University
University of Ottawa

Child Development Centre, Hotel Dieu
Hospital
Montreal Children’s Hospital
Stan Cassidy Rehabilitation Centre

Queen’s University

IWK Health Centre
Winnipeg Health Sciences Centre

Dalhousie University
University of Manitoba

Dr. Maryam Oskoui
Dr. Colleen O’Connell
and
Dr. Scott Worley
Dr. Joseph Dooley
Dr. Edward Leung

Erin Oak Kids Centre for Treatment
and Development

None

Dr. Gillian Hogan
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McGill University
University of New Brunwick/
Dalhousie University
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patients, 37 registries that enroll SMA patients, 14 registries that
enroll DM patients and 1 of 4 registries that enroll LGMD patients
worldwide (11). The CNDR is unique among many NM registries
in that it is a multi-disease registry with participants enrolled and consented directly in NM clinics with clinic verified data. The strengths
of the design and organization of the CNDR have led to a number of
successes for the paediatric NM community in Canada.

Success in clinical trial facilitation
Canada is currently without a defined orphan disease strategy,
or even an orphan disease designation within the Health Canada

Others
16%

Charcot-MarieTooth Disease
9%

Dystrophinopathies
40%

Myotonic Dystrophy
9%

Spinal Muscular
Atrophy
16%

Limb Girdle
Muscular
Dystrophies
10%

Figure 1. Breakdown of paediatric diseases in the Canadian
Neuromuscular Disease Registry. Dystrophinopathies include Duchenne,
Becker and intermediate muscular dystrophies. A detailed breakdown of
other neuromuscular disorders can be found in Table 4

pharmaceutical review process, which limits the incentive for
drug development in rare diseases (12). Despite this disadvantage of working in Canada, the launch of the CNDR has nonetheless encouraged more industry partners to consider establishing
clinical trial sites in Canada. In our view, the development of the
CNDR has therefore allowed Canada to be viewed more favourably by biopharmaceutical companies involved in drug development leading to clinical trial opportunities for Canadian NM
patients. The CNDR is now exploring models for post-marketing
surveillance for new therapies to further enhance the attractiveness of Canada as a market for novel therapeutics.
Registry information can also benefit research at the pre-clinical
stage prior to human study. For example, a theoretical bioinformatics study using the DMD registry in France has allowed for the
prediction that development of a multi-exon skipping antisense oligonucleotide could help 63% of patients with dystrophin deletions,
in contrast to single exon skipping of even the most frequently
deleted exons which would help only 16% of affected boys (13).
Although randomized clinical trials (RCTs) are the gold standard for providing clinical evidence to guide treatment decisions,
the costs of RCTs in the rare disease population are prohibitive and
participants are not always representative of the patient population
at large. One proposed solution is registry-based RCTs (14,15).
This type of trial design has been used an open-label method to
evaluate treatments, strategies and devices. The baseline and end
points are already included in the database. Registry-based clinical
trials are relatively simple to design, far less costly and more applicable to real-world patients compared with RCTs. The CNDR is
an ideal registry for identifying patients eligible for enrollment in
registry-based randomized trials.

Success in facilitating other clinical research
Although the planning, facilitation and implementation of
clinical trials are paramount objectives for the CNDR, it
also enables many other important research initiatives. The

Table 2. Diagnostic and genetic characteristics of paediatric patients with dystrophinopathies, SMA and DM
Diagnosis (N)

Breakdown by disease subtype

Dystrophinopathies
(245)

Duchenne

Becker

Intermediate

Mutation types

224

18

3

Deletions

Duplications

Point mutations

Negative

Unknown

162

25

28

5

29

SMA (98)

DM (58)

Genetic information

Type 1

Type II

Type III Distal SMA Unknown* SMN2 copy numbers

28

46

19

3

2

Type I (N = 23)

Type II (N = 27)

Type III (N = 7)

2.3

3.0

3.7

Congenital DM

DM type I

Average number of CTG repeats

30

22

Congenital (N = 24)

DM1 (N = 18)

1469

650

DM Myotonic dystrophy; SMA Spinal muscular atrophy; SMN2 Survivor motor neuron 2. *SMA was originally a pending disease and disease
subtype information was not collected
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Table 3. Clinical characteristics of paediatric patients with dystrophinopathies, spinal muscular atrophy and myotonic dystrophy

Diagnosis (N)

Average
Clinical trial
age (years) participation

Dystrophinopathies (249) 12
Spinal muscular
9
atrophy (85)*
Myotonic dystrophy (58) 10

Ambulation (N)

Non-invasive
ventilation (N)

Yes (no,
unknown)

Yes

60 (148, 41)
3 (49, 33)

178 45
7 34

25
6

6
24

39 12

7

6

No data

No Unknown Yes

No

Unknown Yes

216 25
46 15
43

Invasive
ventilation (N)

9

0
2
3

No

Unknown

224 25
68 15
46

9

*Only includes spinal muscular atrophy patients for whom medical information is available (i.e., indexed patients)

Table 4. Non-index diseases included in the CNDR

Muscle (N=40)

Nerve (N=18)

Congenital muscular
Friedreich’s ataxia (8)
dystrophy (20)
Congenital muscular dystrophy— Hereditary sensory autonomic
Merosin deficiency (7)
neuropathy (4)
Mitochondrial myopathy (2)
Facioscapulohumeral muscular
dystrophy (7)
Myotonia congenita—Thomsen
disease (2)
Paramyotonia congenital (4)
Dermatomyositis (1)
King-Denborough disease (1)
X-linked myopathy with excessive
autophagy (1)

Neuromuscular junction (N=13)

Other (N=11)

Myasthenia gravis (7)
Myasthenia gravis—ocular (1)
Myasthenic syndrome/congenital
myasthenic syndrome (5)

Arthrogryposis (5)
Amyoplasia (5)
Motor neuron
disease (1)

Chronic inflammatory
demyelinating
polyneuropathy (1)
Dejerine-Sottas disease (1)
Hereditary neuralgia
amyotrophy (1)
Hereditary neuropathy with
liabilitiy to pressure palsies (2)
Peripheral neuropathy (1)

Poland syndrome (1)

CNDR Canadian Neuromuscular Disease Registry; PTEN Phosphatase and tensin homolog

CNDR has facilitated a variety of clinical and survey-based
studies including the ongoing longitudinal study examining
health-related quality of life (HRQOL) in boys with DMD.
This is one of the largest and most representative HRQOL
studies in this population and has already yielded intriguing
results. Notably, subjective levels of fatigue were found to be
highly associated with HRQOL, suggesting reducing levels of
fatigue could lead to improvement of HRQOL in the paediatric DMD population (9). The CNDR plays a crucial role
in the ongoing success of this project, from assisting with
patient enrollment through study notifications and providing
accurate clinical data.
The CNDR can also foster collaborations between specialists
in the NM field and paediatricians and paediatric health care
professionals from other disciplines, studying a wide range
of issues, such as those pertaining to chronic disease, genetic
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disorders, transition to adult care, end-o-life care, quality of life,
health service delivery and health maintenance.

Multi-disease, clinic-based model optimizes efficiency
and accuracy of data collection
The CNDR is a comprehensive registry that has the capacity to enroll all patients with a NM disease. While DMD,
DM, LGMD and SMA are the diseases of focus, there is
value in collecting basic demographic information on
other NM diseases. These diseases are even more rare, thus
recruitment for clinical trial and other research studies is
even more challenging. A centrally managed database that
harmonizes participant information collection is the most
efficient way of achieving this goal, ensuring that participants with even the rarest NM diseases are not overlooked
for research.
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The decision to run a clinic-based enrollment and data entry
model for the CNDR was based on several goals: retaining participants through regular clinic contact, increasing the accuracy
of data through data collection from clinic charts by trained
personnel and assuring full and ongoing informed consent. The
inadequacy of follow-up in self-report registries has been outlined in a paper contrasting an active surveillance registry with
a patient-driven registry for DM; these include several clinically relevant pieces of information being missing and concerns
regarding accuracy of reported data due to recall bias (16).

Potential as a clinic-management tool and
epidemiologic tool
Although NM diseases are known to comprise a sizeable component of the neurological burden of disease globally, the
epidemiologic data available for specific NM diseases in Canada
or globally remain very limited. In this regard, CNDR data have
already contributed to global collection of epidemiological data,
ranging from mutation types and frequencies (17) to monitoring of disease trends and care practices (18). However, at present, there are gaps in patient recruitment as not all Canadian
paediatric NM clinics are enrolling in the CNDR, and so the
CNDR numbers should not be considered a comprehensive
epidemiological tool. A registry that is embedded within the
clinic setting can have a beneficial quality assurance impact,
ensuring that patients are not ‘falling through the cracks’ of a
busy practice, flagging that a participant is overdue for a visit or
has not had a certain test at the indicated time. Further, national
practice differences can be examined using registry data as has
been done for cystic fibrosis resulting in advanced and more
codified standards of care (19). The CNDR aims to increase
this potential function of the registry over time.

Funding model
The CNDR has a unique funding structure: it is funded by a
mix of charitable and industry sponsors and entirely unfunded
by government or research grant agencies. Each sponsor
assumes a portion of the registry’s central operating costs and
covers disease-specific costs for their disease of choice. In this
way, each sponsoring organization is able to minimize individual costs while maximizing collective benefit and multiplying
the value of every dollar invested.

CONCLUSIONS
The CNDR is a clinic-based registry of national scope that has
been successful in connecting Canadian NM patients to national
and international clinical trials and other research initiatives. With
the recent launch of a national rare disease strategy, the advent of
next-generation sequencing diagnoses, the burgeoning interest
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of pharmaceutical and biotechnology industries in rare disease
and the resulting rare disease therapeutic pipeline, there will be
increasing focus on, and opportunities for, rare disease clinical
trials for NM diseases. The CNDR will act as a valuable resource
enabling capture of national data and facilitating a network of
geographically disparate teams to help to rectify this gap. The
registry will continue to engage stakeholders to enable and support research into potential treatments, with specific measures of
success being the number of studies and publications with high
impact that are realized due to the CNDR. Paediatric clinicians
and researchers are encouraged to submit research proposals or
data requests that will engage the Canadian paediatric NM community and ultimately deliver benefits to NM patients.
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